Back to first-pass browser

First-pass extracted concept

CAR-NK and CAR-macrophage platforms

Candidate: concept label1 source documents3 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Aliases

alternative immune cells for CAR therapy

Extracted Explainers

What the tool is doing

These platforms use alternative immune effector cells, specifically NK cells and macrophages, for CAR-based therapy.

Source 1DOIPubMed

Resources required

The abstract supports that NK-cell or macrophage-based CAR platforms are required, but does not specify manufacturing details.

Source 1DOIPubMed

What problem it solves

They are presented as ways to overcome some limitations of conventional T-cell therapies, including fratricide and allogeneic-use challenges.

Source 1DOIPubMed

What it does not solve

The abstract does not show that these alternative cell platforms fully solve AML target-specificity or relapse problems.

Source 1DOIPubMed

Alternatives

The abstract contrasts these platforms with conventional CAR-T fine-tuning strategies such as logic gating, controllable switches, adapter CARs, and persistence engineering.

Source 1DOIPubMed

Evidence Snippets

Finally, alternative immune cells, including natural killer (NK) cells and macrophages, provide versatile platforms that may overcome limitations of conventional T-cell therapies, such as fratricide or challenges in allogeneic use.
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1capabilitysupports2025Source 1DOIPubMed

Alternative immune cells including NK cells and macrophages may overcome limitations of conventional T-cell therapies such as fratricide or challenges in allogeneic use.

Quoted textsource-backed
alternative immune cells, including natural killer (NK) cells and macrophages, provide versatile platforms that may overcome limitations of conventional T-cell therapies, such as fratricide or challenges in allogeneic use
Claim 2limitationsupports2025Source 1DOIPubMed

CAR T-cell therapy in AML has been limited by early relapses and severe toxicities.

Quoted textsource-backed
its application in AML has been limited by early relapses and severe toxicities
Claim 3mechanism or rationalesupports2025Source 1DOIPubMed

Most AML-associated surface antigens are also expressed on healthy hematopoietic stem and progenitor cells, creating risks of on-target/off-tumor toxicity and prolonged myeloablation.

Quoted textsource-backed
most AML-associated surface antigens are also expressed on healthy hematopoietic stem and progenitor cells, creating significant risks of on-target/off-tumor toxicity and prolonged myeloablation